Belgian biotech Galapagos (Nasdaq: GLPG) has agreed to sell its Jyseleca (filgotinib) business to Italian drugmaker Alfasigma.
The firms have signed a letter of intent concerning the transfer, which includes the European and UK Marketing Authorizations, as well as the commercial, medical and development activities in 14 European countries.
Around 400 full-time positions across these activities are included in the business.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze